Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer
Armata Pharmaceuticals (NYSE American: ARMP) has appointed David House as Senior Vice President, Finance, effective August 16th. House brings extensive experience in senior accounting and finance roles within life sciences companies. CEO Dr. Deborah Birx highlighted House's expertise as valuable for advancing Armata's programs, AP-PA02 and AP-SA02, and preparing for pivotal studies next year.
House's previous roles include Corporate Controller at ZO Skin Health, where he managed global accounting operations and financial reporting. He also held key positions at Peregrine Pharmaceuticals and Avid Bioservices, implementing ASC 606 and managing SEC reporting. House's career spans various accounting and financial management positions in healthcare and technology sectors. He holds a Bachelor's degree in Business Administration with an Accounting concentration and has previously held a California CPA license.
Armata Pharmaceuticals (NYSE American: ARMP) ha nominato David House come Vicepresidente Senior, Finanza, con effetto dal 16 agosto. House porta un'ampia esperienza in ruoli senior di contabilità e finanza all'interno di aziende nel settore delle scienze della vita. La CEO Dr.ssa Deborah Birx ha evidenziato l'esperienza di House come un valore per far avanzare i programmi di Armata, AP-PA02 e AP-SA02, e per prepararsi agli studi cruciali dell'anno prossimo.
I ruoli precedenti di House includono quello di Corporate Controller presso ZO Skin Health, dove ha gestito le operazioni contabili globali e la rendicontazione finanziaria. Ha ricoperto anche posizioni chiave presso Peregrine Pharmaceuticals e Avid Bioservices, implementando l'ASC 606 e gestendo la rendicontazione SEC. La carriera di House comprende vari ruoli di contabilità e gestione finanziaria nei settori della sanità e della tecnologia. Ha conseguito una laurea in Amministrazione Aziendale con specializzazione in Contabilità e in passato ha detenuto una licenza CPA della California.
Armata Pharmaceuticals (NYSE American: ARMP) ha nombrado a David House como Vicepresidente Senior de Finanzas, con efecto a partir del 16 de agosto. House aporta una amplia experiencia en roles de contabilidad y finanzas de alto nivel dentro de empresas de ciencias de la vida. La CEO Dra. Deborah Birx destacó la experiencia de House como valiosa para avanzar en los programas de Armata, AP-PA02 y AP-SA02, y para prepararse para estudios clave el próximo año.
Los roles anteriores de House incluyen Corporate Controller en ZO Skin Health, donde gestionó las operaciones contables globales y la presentación de informes financieros. También ocupó posiciones clave en Peregrine Pharmaceuticals y Avid Bioservices, implementando ASC 606 y gestionando informes a la SEC. La carrera de House abarca varios puestos en contabilidad y gestión financiera en los sectores de la salud y la tecnología. Tiene una licenciatura en Administración de Empresas con concentración en Contabilidad y ha tenido previamente una licencia de CPA de California.
Armata Pharmaceuticals (NYSE American: ARMP)는 David House를 재무 부사장으로 임명했습니다, 8월 16일부터 발효됩니다. House는 생명 과학 회사의 고위 회계 및 재무 역할에서 광범위한 경험을 가지고 있습니다. CEO Dr. Deborah Birx는 House의 전문성이 Armata의 프로그램인 AP-PA02 및 AP-SA02를 발전시키고 내년의 주요 연구를 준비하는 데 가치가 있다고 강조했습니다.
House의 이전 직책으로는 ZO Skin Health에서 Corporate Controller로 근무하며 글로벌 회계 운영 및 재무 보고를 관리했습니다. 그는 또한 Peregrine Pharmaceuticals 및 Avid Bioservices에서 ASC 606을 구현하고 SEC 보고를 관리하며 핵심 직책을 맡았습니다. House의 경력은 의료 및 기술 분야에서 다양한 회계 및 재무 관리 직책을 포함합니다. 그는 회계 전공으로 경영학 학사 학위를 보유하고 있으며, 이전에 캘리포니아 CPA 면허를 취득한 바 있습니다.
Armata Pharmaceuticals (NYSE American: ARMP) a nommé David House au poste de Vice-Président Senior, Finances, à compter du 16 août. House apporte une vaste expérience dans des fonctions de comptabilité et de finance au sein d'entreprises de sciences de la vie. La CEO Dr. Deborah Birx a souligné que l'expertise de House est précieuse pour faire avancer les programmes d'Armata, AP-PA02 et AP-SA02, et pour se préparer aux études clés de l'année prochaine.
Les rôles précédents de House incluent celui de Corporate Controller chez ZO Skin Health, où il a géré les opérations comptables mondiales et les rapports financiers. Il a également occupé des postes clés chez Peregrine Pharmaceuticals et Avid Bioservices, en mettant en œuvre l'ASC 606 et en gérant les rapports à la SEC. La carrière de House couvre divers postes en comptabilité et gestion financière dans les secteurs de la santé et de la technologie. Il est titulaire d'un diplôme de Bachelor en Administration des Affaires avec une spécialisation en Comptabilité et a précédemment détenu une licence CPA de Californie.
Armata Pharmaceuticals (NYSE American: ARMP) hat David House zum Senior Vice President für Finanzen ernannt, mit Wirkung zum 16. August. House bringt umfangreiche Erfahrungen in leitenden Positionen in der Buchhaltung und Finanzen in Unternehmen der Lebenswissenschaften mit. CEO Dr. Deborah Birx hob Houses Fachwissen als wertvoll für die Weiterentwicklung von Armatas Programmen, AP-PA02 und AP-SA02, sowie für die Vorbereitung auf wichtige Studien im nächsten Jahr hervor.
Houses frühere Positionen umfassen Corporate Controller bei ZO Skin Health, wo er die globalen Buchhaltungsoperationen und die Finanzberichterstattung leitete. Er hatte auch Schlüsselpositionen bei Peregrine Pharmaceuticals und Avid Bioservices inne, implementierte ASC 606 und verwaltete die SEC-Berichterstattung. Houses Karriere umfasst verschiedene Positionen in der Buchhaltung und Finanzmanagement in den Bereichen Gesundheitswesen und Technologie. Er hat einen Bachelor-Abschluss in Betriebswirtschaft mit einer Spezialisierung auf Rechnungswesen und hatte zuvor eine CPA-Lizenz in Kalifornien.
- Appointment of experienced finance executive David House as SVP of Finance
- Strengthening of financial leadership as the company prepares for pivotal studies in 2025
- House's expertise in managing global accounting operations and financial reporting for clinical and commercial stage companies
- None.
"We are delighted to welcome David to the Armata team," stated Dr. Deborah Birx, Chief Executive Officer of Armata. "David's extensive experience and track record of serving in senior accounting and finance roles within both clinical and commercial stage life sciences companies will serve us well as we continue to advance our two distinct programs – AP-PA02 and AP-SA02 – and prepare to initiate pivotal studies next year. This is an exciting time at Armata, and the addition of David to our senior team helps ensure that we are best positioned to achieve long-term success as we work to introduce an exciting new class of anti-infectives to treat serious drug-resistant bacterial infections."
Before joining Armata, Mr. House served as Corporate Controller and Vice President of Accounting at ZO Skin Health, Inc., a multi-channel physician-dispensed skincare company, from October 2018 to May 2024. At ZO Skin Health, he led global accounting operations, managed financial reporting, and played a crucial role in the company's acquisition by Blackstone. He also established international subsidiaries and oversaw financial integration for mergers and acquisitions. Mr. House's experience includes similar financial leadership roles at Peregrine Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, and Avid Bioservices, Inc. (CDMO), a contract development and manufacturing organization where he served as Controller and was responsible for implementing ASC 606, managing technical accounting, and conducting Securities and Exchange Commission (the "SEC") reporting.
Mr. House's career also includes roles at Viant, Inc. (DSP), Sourcing Solutions, LLC, and Apria Healthcare (APR), where he held various accounting and financial management positions. In the early stages of his career, Mr. House worked as a Senior Auditor at Windes, a public accounting firm. There, he managed comprehensive audits for public, private, and not-for-profit entities and contributed to SEC filings and internal control evaluations. Mr. House holds a Bachelor of Arts in Business Administration with an Accounting concentration from California State University,
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.
Forward Looking Statements
This communication contains "forward-looking" statements as defined by the Private Securities Litigation Reform Act of 1995. These statements relate to future events, results or to Armata's future financial performance and involve known and unknown risks, uncertainties and other factors which may cause Armata's actual results, performance or events to be materially different from any future results, performance or events expressed or implied by the forward-looking statements. In some cases, you can identify these statements by terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative of those terms, and similar expressions. These forward-looking statements reflect management's beliefs and views with respect to future events and are based on estimates and assumptions as of the date of this communication and are subject to risks and uncertainties including risks related to Armata's development of bacteriophage-based therapies; ability to staff and maintain its production facilities under fully compliant current Good Manufacturing Practices; ability to meet anticipated milestones in the development and testing of the relevant product; ability to be a leader in the development of phage-based therapeutics; ability to achieve its vision, including improvements through engineering and success of clinical trials; ability to successfully complete preclinical and clinical development of, and obtain regulatory approval of its product candidates and commercialize any approved products on its expected timeframes or at all; and Armata's estimates regarding anticipated operating losses, capital requirements and needs for additional funds. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 21, 2024, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-appointment-of-life-sciences-accounting-and-finance-veteran-david-house-as-svp-of-finance-and-principal-financial-officer-302223771.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
Who is the new SVP of Finance at Armata Pharmaceuticals (ARMP)?
What is David House's background before joining Armata Pharmaceuticals (ARMP)?
When does Armata Pharmaceuticals (ARMP) plan to initiate pivotal studies for its programs?
What are the main programs Armata Pharmaceuticals (ARMP) is developing?
